MYC and neoplasm: To prove the MYC-mRNA drug safety in the tumor-bearing mice compared to healthy controls, we collected blood on day 25 (Figure 1A) to assay the blood cells, electrolytes, liver enzymes, kidney function, and pancreatic and biliary function analysis from the 3× IC50 group (Supplementary Table S1, Supplementary Table S2).